IPRE..look at what JAV has done
some dd
Pinnacle Digest: Subsidiary Recieves License: Spurs Review
3/13/2007 5:06:06 AM
Mar 13, 2007 (M2 PRESSWIRE via COMTEX) -- To read this review in its entirety, please visit www.pinnacledigest.com.
Javelin Pharmaceuticals, Inc. ( JAV ) experienced a slight increase of 0.54% accompanied by 210,200 shares traded. They recently announced that the British Medicines and Healthcare Products Regulatory Agency (MHRA) have granted a Wholesale Dealer's License to Javelin's UK subsidiary, Javelin Pharmaceuticals UK Limited. PinnacleDigest is looking closely into this License as it will enable Javelin Pharmaceuticals UK to expand and promote their products accordingly.
As stated in past articles acquisitions and alliances of biotechnology companies have been on the rise of late. This fact becomes very clear when reviewing the figures of last year. Bigger drug makers can foresee a future in which the environment and demand for drugs is a very positive one over the coming 25 years.
At PinnacleDigest we strive to not only bring you an unbiased, informative, broad approach to the industry, but to specifically analyze specific companies in respect to that approach. The first step in this process is to review the company in contrast to the influences within the sector affecting them. To continue with this review in its entirety, come explore our growing online financial magazine at www.pinnacledigest.com.
Rep. Patrick Kennedy is planning to initiate the use of personal health records through a trust fund that pays doctors. The new version of his bill was introduced March 1.
It is known as the Personalized Health Information Act and would require the Department of Health and Human Services to create a public-private PHR incentive program and trust fund to pay physicians. Physicians would be paid up to three years and at least $3 per eligible patient enrolled to use a PHR. We will come back to this issue and its possible long term affects on this company and the healthcare sector.
In respect to Javelin Pharmaceuticals this new license for the subsidiary represents a key commercialization step in anticipation of the product launch for Dyloject (diclofenac sodium 75mg / 2mL). Dyloject is currently under review for Marketing Authorization Application (MAA) approval in the UK also by the MHRA. This approval will be awaited with great anticipation by our team at PinnacleDigest. We will also be closely monitoring the relevant market and this drugs potential integration into it. To follow up with Javelin Pharmaceuticals and to learn more about the sector which influences them so greatly, visit us at www.pinnacledigest.com.
To continue with this report as well as other related articles, please visit www.pinnacledigest.com for a complimentary membership. It should be stated that our membership requires no commitment to our service. If you would like to contact us please write to support@pinnacledigest.com.
PinnacleDigest has no vested interest in the company mentioned herein. This source of information is from an unbiased perspective. If you wish to become a member of www.pinnacledigest.com you will be gaining access to articles similar to this one and many other useful services we know you will find valuable. Keeping you educated and up-to-date with the market is one of our main purposes. Our approach in achieving this goal and our ability to consistently deliver high quality investment material is what defines our business model.
Investors seeking a distinctive approach to investing should also visit www.pinnacledigest.com for a complimentary membership.
About Pinnacle Digest
Pinnacledigest.com is an emerging online financial newsletter community. We put together informative material, capturing the information that we know will give you an edge to your portfolio and more specifically your investment approach.
Once a member of PinnacleDigest you will be able to access our complimentary full-length research reports on selected companies, our weekly volumes, and our market overviews. In addition to these services we are confident you will enjoy our many other services, as well as our main feature which is available to all our members.
We pride ourselves in having a multi purpose online magazine and encourage you to join our community.
This
AI
